Hypoxia response and cancer stem cell pathway components

The hypoxia response and cancer stem cell (CSC) pathway components comprise a network of molecular drivers that allow tumors to adapt to low-oxygen environments and maintain a population of self-renewing, therapy-resistant cells. The primary mediators are the hypoxia-inducible factors (HIFs), specifically HIF-1α and HIF-2α, which stabilize under hypoxic conditions and activate the transcription of genes involved in angiogenesis, glycolysis, and pH regulation. These factors are intrinsically linked to the cancer stem cell phenotype, as they directly or indirectly activate stemness-related transcription factors like OCT4 and SOX2, as well as signaling pathways such as Notch and Wnt/β-catenin. This interplay promotes the survival of CSCs in the hypoxic niche, contributing to tumor heterogeneity and resistance to conventional chemotherapy and radiation. Therapeutic targeting of these components aims to disrupt the protective hypoxic environment and sensitize CSCs to treatment. Current pharmacological strategies include direct HIF inhibitors, such as Belzutifan, and inhibitors of downstream effectors like Carbonic anhydrase IX (CA9). Additionally, agents targeting the crosstalk between hypoxia and stemness pathways are being explored to prevent metastasis and disease relapse. However, targeting these pathways presents challenges due to the essential roles of HIFs and stem cell signaling in normal physiological processes like erythropoiesis and tissue regeneration.

Other names

Hypoxia-inducible factor and cancer stem cell signaling pathwayHIF-CSC axisHypoxia-mediated stemness pathwayHypoxia-inducible factor signaling pathway

Inhibition of HIF-1α/HIF-2α stabilization and transcriptional activity, blockade of hypoxia-responsive elements (HRE), and inhibition of downstream cancer stem cell maintenance signals such as Notch, Wnt, and Carbonic anhydrase IX.